Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303913 | 1.00 | PDGFRB (0.71) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL5459683 | 1.00 | PDGFRB (0.71) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL7254720 | 0.85 | PDGFRB (0.65) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL563573 | 0.83 | PDGFRB (0.73) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3164867 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3164863 | 0.83 | PDGFRB (1.00) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL563572 | 0.83 | PDGFRB (0.73) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL15850346 | 0.82 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2056162 | 0.82 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10162435 | 0.82 | PDGFRB (0.67) | PDGFRBPDGFRARAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | claimed |
| CN-102766089-A | 3-(3-quinolyl)-2-propenyl-1-halide and its preparation method | SHANGHAI INST PHARM INDUSTRY | 2012-11-07 | — | — | CN | disclosed |
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2006078450-A1 | 9A, 11-2C-BICYCLIC 9A-AZALIDE DERIVATIVES | ENANTA PHARMACUETICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-6590083-B1 | Compounds of given formula; erythromycin derivatives; useful in the treatment of bacterial and protozoal infections and conditions involving gastric motility | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-08 | — | — | US | disclosed |
| EP-1272500-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSITUTED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1192139-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | Abbott Laboratories (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001000582-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000078773-A2 | PROCESS FOR PREPARING 6-O-ALKENYL-SUBSTITUTED ERYTHROMYCIN DERIV ATIVES | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | CYP3A7, CYP2C8, CYP51A1 | PDGFRB 3510/4885PDGFRA 2748/4885RAB9A 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.